https://www.yiliao.com/index.php?action=history&feed=atom&title=FGFR2%E8%9E%8D%E5%90%88
FGFR2融合 - 版本历史
2026-04-19T00:57:34Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=FGFR2%E8%9E%8D%E5%90%88&diff=314406&oldid=prev
223.160.138.92：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-14T08:08:08Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[FGFR2融合]]</strong>（FGFR2 Gene Fusions）是指 <em>FGFR2</em> 基因与另一个伴侣基因发生染色体重排而形成的嵌合基因。这种融合最常发生于 <strong>[[肝内胆管癌]]</strong>（iCCA），在约 10%–15% 的患者中被检测到。融合蛋白保留了完整的激酶结构域，通过二聚化引发持续的下游信号转导（如 MAPK、PI3K/AKT 通路），从而驱动肿瘤的增殖和存活。作为一种强效的致癌驱动因子，FGFR2 融合被认为是“可成药”靶点的典范。目前，针对该靶点的 <strong>[[FGFR抑制剂]]</strong> 已显著改善了晚期经治胆管癌患者的生存预后。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">FGFR2 融合</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">驱动基因 · 胆管癌核心靶点</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">病理特征：激酶域持续激活</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">染色体位置：10q26.13 (FGFR2)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2263</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3689</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">常见伴侣基因</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">BICC1, AHCYL1, CCDC6</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">高发癌种</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">肝内胆管癌 (iCCA)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">检测技术</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">NGS (DNA/RNA), FISH</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">获批药物</th><br />
<td style="padding: 12px; color: #0f172a;">[[佩米替尼]]•[[福替巴替尼]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：结构重排驱动的异常信号</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
FGFR2 融合蛋白的致癌性源于其结构的改变及下游通路的过度激活：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>组成性二聚化：</strong> 伴侣基因（如 <em>BICC1</em>）通常包含卷曲螺旋结构域（Coiled-coil domain），介导 FGFR2 融合蛋白发生配体非依赖性的物理接触与二聚化。</li><br />
<li style="margin-bottom: 12px;"><strong>激酶级联激活：</strong> 二聚化导致 FGFR2 胞内激酶域发生交叉磷酸化，随后招募 FRS2 蛋白，激活 <strong>[[RAS/MAPK]]</strong>、<strong>[[PI3K/AKT/mTOR]]</strong> 和 <strong>[[JAK/STAT]]</strong> 等促生存通路。</li><br />
<li style="margin-bottom: 12px;"><strong>上皮-间质转化 (EMT)：</strong> 持续的 FGFR2 信号不仅促进细胞增殖，还增强了胆管上皮细胞的迁移和侵袭能力，导致肿瘤早期发生微转移。</li><br />
</ul><br />
[Image showing the process of FGFR2 gene fusion and the resulting constitutive intracellular signaling]<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心靶向治疗药物对比</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">通用名</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">结合方式</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床价值/耐药应对</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[佩米替尼]] (Pemigatinib)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">可逆性 ATP 竞争型</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">全球首个获批；对于 <strong>FGFR2 敏感型</strong> 融合展现高效缓解。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[福替巴替尼]] (Futibatinib)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">不可逆性共价结合</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>克服部分耐药</strong>；对多种 ATP 口袋变异（如 N549K）具有强力活性。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[英菲格拉替尼]] (Infigratinib)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">可逆性 ATP 竞争型</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在胆管癌和 <strong>软骨发育不全</strong> 领域均有重要布局。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从精准检测到全病程管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
FGFR2 融合阳性患者的诊疗需强调多学科联合管理：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>检测时机与方法：</strong> NCCN 及 CSCO 指南推荐对于所有晚期 iCCA 患者常规进行 <strong>[[二代测序]]（NGS）</strong>。推荐采用 RNA-seq 或大板 DNA-NGS 以减少对罕见伴侣基因融合的漏检。</li><br />
<li style="margin-bottom: 12px;"><strong>副作用前置管控：</strong> <strong>[[高磷血症]]</strong> 是该靶点的特征性副反应（发生率 > 90%）。治疗初期即需监测血磷，并根据分级采取低磷饮食或加用磷结合剂。</li><br />
<li style="margin-bottom: 12px;"><strong>耐药监控：</strong> FGFR2 融合患者在靶向治疗后常出现 <strong>[[V564F]]</strong>（守门基因）或胞外域突变。建议在耐药进展后进行液体活检（ctDNA），以指导序贯二代/三代抑制剂。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[BICC1]]：</strong> FGFR2 融合中最常见的伴侣基因。</li><br />
<li style="margin-bottom: 8px;"><strong>[[高磷血症]]：</strong> 靶向 FGFR 信号轴后，干扰 FGF23 调节导致的代谢类效应。</li><br />
<li style="margin-bottom: 8px;"><strong>[[肝内胆管癌]] (iCCA)：</strong> FGFR2 融合的标志性适应症。</li><br />
<li style="margin-bottom: 8px;"><strong>[[合成致死]] (研究前沿)：</strong> 探索 FGFR 抑制剂与 DNA 损伤修复抑制剂的协同应用。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Abou-Alfa GK, et al. (2020).</strong> <em>Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, single-arm, phase 2 study (FIGHT-202).</em> <strong>[[The Lancet Oncology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：FIGHT-202 试验首次在全球范围验证了 FGFR2 融合作为胆管癌精准治疗靶点的临床获益。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Goyal L, et al. (2023).</strong> <em>Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma (FOENIX-CCA2).</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[临床价值]：本研究确立了不可逆共价抑制剂在应对获得性耐药及提高响应率方面的卓越地位。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
FGFR2 融合诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FGFR2]]•[[FGF23]]•[[MAPK 通路]]•[[PI3K 通路]]•[[BICC1]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[佩米替尼]]•[[福替巴替尼]]•[[英菲格拉替尼]]•[[厄达替尼]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Incyte]]•[[Taiho Pharma]]•[[Foundation Medicine]]•[[NMPA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[液体活检监测耐药突变]]•[[一线治疗对比化疗三期临床]]•[[针对胞外域点突变的抑制剂研发]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.92